Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality

被引：127

作者：

Myasoedova E. ^{[1
]}

Davis III J.M. ^{[2
]}

Crowson C.S. ^{[2
]}

Gabriel S.E. ^{[1
]}

机构：

[1] Department of Health Sciences Research, Mayo Clinic, Rochester, MN

[2] Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905

来源：

Current Rheumatology Reports | 2010年 / 12卷 / 5期

关键词：

Accelerated aging; CV disease; Inflammation; Mortality; Rheumatoid arthritis;

D O I：

10.1007/s11926-010-0117-y

中图分类号：

学科分类号：

摘要：

Increased mortality in rheumatoid arthritis (RA) is widely recognized but not fully explained. Despite substantial improvements in management and growing knowledge of the determinants of increased mortality, evidence for reduction in mortality in RA has lagged behind. Indeed, most studies report no apparent reduction in mortality in RA. However, emerging evidence from some recent RA inception cohorts suggests no increased mortality, including cardiovascular mortality, but this awaits further confirmation. Although it is possible that recent advances in RA treatment may manifest in improvement of survival in the near future, other factors, including undertreated or unrecognized low-grade inflammation, comorbidities, and immunogenetic factors, may contribute to the excess mortality in RA and impede its improvement. In this review, we summarize the current knowledge of the rates and determinants of mortality in RA, identify and discuss potential explanations for excessmortality, and outline promising research avenues for targeting mortality in RA. © Springer Science+Business Media, LLC 2010.

引用

页码：379 / 385

页数：6

共 50 条

[31]

Koivuniemi R., Paimela L., Suomalainen R., Et al., Causes of death in patients with rheumatoid arthritis autopsied during a 40- year period, Rheumatol Int, 28, pp. 1245-1252, (2008)

[32]

Goulenok T.M., Meune C., Gossec L., Et al., Usefulness of routine electrocardiography for heart disease screening in patients with spondyloarthropathy or rheumatoid arthritis, Joint Bone Spine, 77, pp. 146-150, (2010)

[33]

Choy E., Sattar N., Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actions, Ann Rheum Dis, 68, pp. 460-469, (2009)

[34]

Peters M.J., Symmons D.P., McCarey D., Et al., EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Ann Rheum Dis, 69, pp. 325-331, (2010)

[35]

Coyne P., Hamilton J., Heycock C., Et al., Acute lower respiratory tract infections in patients with rheumatoid arthritis, J Rheumatol, 34, pp. 1832-1836, (2007)

[36]

Saba N.S., Kosseifi S.G., Charaf E.A., Hammad A.N., Adalimumabinduced acute myelogenic leukemia, South Med J, 101, pp. 1261-1262, (2008)

[37]

Burmester G.R., Mease P., Dijkmans B.A., Et al., Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases, Ann Rheum Dis, 68, pp. 1863-1869, (2009)

[38]

Naranjo A., Sokka T., Descalzo M.A., Et al., Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study, Arthritis Res Ther, 10, (2008)

[39]

Carmona L., Descalzo M.A., Perez-Pampin E., Et al., All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists, Ann Rheum Dis, 66, pp. 880-885, (2007)

[40]

Van Tuyl L.H., Boers M., Lems W.F., Et al., Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis, Ann Rheum Dis, 69, pp. 807-812, (2010)

← 1 2 3 4 5 →